EGFR and colorectal carcinoma: Ponsioen et al. demonstrated that EGFR activity activated MAPK signaling in BRAF/KRAS mutant CRC PDOs, providing a mechanism of the validity of EGFR inhibition within combination treatment for KRAS/BRAF mutant CRC patients [93].